Figure 3.

CCND1 generates different prognostic outcomes in various tumors. Expression of CCND1 is differentially increased in BRCA in distinct subclasses of BRCA, and CCND1 was negatively related to miR-93-5p. (A-G) High expression of CCND1 resulted in poor prognosis in pancreatic ductal adenocarcinoma, testicular germ cell tumor, and thymoma according to the Kaplan-Meier Plotter datasets; (H-K) high expression of CCND1 conveyed good prognosis in kidney renal clear cell carcinoma, stomach adenocarcinoma, thyroid carcinoma, and uterine corpus endometrial carcinoma according to Kaplan-Meier Plotter datasets; (L) CCND1 was increased in BRCA according to UALCAN datasets; (M) CCND1 was increased in the luminal subtype and decreased in the HER2⁺ and TNBA subtypes of BRCA according to UALCAN datasets; (N) CCND1 was negatively correlated with miR-93-5p. ***P<0.001. BRCA, breast cancer.